$SGMT

Ascletis Pharma Inc.'s partner, Sagimet Biosciences, has dosed the first patient in a Phase III U.S. trial of denifanstat (ASC40) for moderate to severe acne. The trial aims to enroll 800 patients. Ascletis' prior Phase III trial in China showed ASC40 was more effective than FDA-approved treatments, with 18.6% treatment success vs. 9.4% for sarecycline and 6.7% for doxycycline.

Sagimet Biosciences (SGMT) started its Phase 3 AURORA trial for denifanstat, a drug for moderate to severe acne. The trial's success could lead to regulatory approval. SGMT has a high P/S ratio of 58.8x, reflecting growth expectations. The company has a GF Score of 34, indicating strong financial stability but weak profitability and growth. Insider selling and cautious institutional sentiment are noted.

Sagimet Biosciences reported progress in its acne trials, with a Phase 3 trial underway and Phase 2 planned for TVB-3567. The company has $257.6M in cash and expects funding through mid-2029. Denifanstat met trial endpoints, and China's NMPA accepted its NDA. Further MASH development depends on non-dilutive funding.

Sagimet Biosciences (SGMT) announced positive 52-week results from a Phase 3 trial of denifanstat for acne, showing 57% IGA success and significant lesion reductions. The trial, conducted by license partner Ascletis in China, supports FASN inhibition as a novel acne treatment. Sagimet is advancing denifanstat into a U.S. Phase 3 trial, with screening underway.

Commodore Capital LP and associates reported a 7.6% ownership stake in Sagimet Biosciences Inc. (SGMT), comprising 5,507,752 shares, including 2,757,742 common shares and 2,750,010 shares acquirable through pre-funded warrants, subject to a 9.99% ownership limit.

HC Wainwright & Co. reiterated a Buy rating on Sagimet Biosciences (SGMT) with a $29 price target, implying a 217.3% upside from the Oct 2 close of $9.14. The firm cited strong efficacy data for denifanstat, showing a 31.7-lesion reduction in acne patients, and favorable long-term safety data. Recent analyst price targets for SGMT range from $10.71 to $38.

Sagimet Biosciences (NASDAQ: SGMT) reported 52-week acne data for denifanstat, showing significant lesion count reductions versus placebo. The company plans to launch a U.S. Phase III trial, AURORA, with 800 patients. Sagimet also announced a $150M financing, extending its cash runway to mid-2029. Denifanstat was well-tolerated, with mild to moderate adverse events. The company is advancing another FASN inhibitor, TVB-3567, through Phase I trials.

Guggenheim reiterated a Buy rating for Sagimet Biosciences with a $26 price target, suggesting a 177.5% upside from the Oct 1 close of $9.37. The firm cited promising Phase 3 trial data for denifanstat, showing strong efficacy and safety in treating acne, aligning with FDA guidance. Recent analyst price targets for SGMT range from $10.71 to $38.

Sagimet Biosciences (SGMT) fell 5% after partner Ascletis Pharma (ASCLF) released 52-week phase 3 trial results for acne drug denifanstat in China. The company also announced a stock offering.

Citizens maintained a Market Outperform rating on Sagimet Biosciences with a $27 price target, implying a 173.3% upside. The company has $366M in cash and expects Phase 3 and 2 data next year. Positive clinical results for denifanstat were also noted.